# A Slightly High Thyroid Number Doesn't Always Need a Pill > Mildly elevated TSH with normal thyroid hormone is common after 60. A large European trial found that treating it in older adults did not improve how people felt. - Publication: New England Anti-Aging (https://newenglandantiaging.com) - Department: The Clinic - Label: Explainer - Section: Hormones - Author: Jess Albrecht, Staff Writer, Hormones - Published: 2026-10-20 - Lead photograph: Round white tablets on a light surface, by Hal Gatewood on Unsplash (https://unsplash.com/photos/round-white-pills-iPl3q-gEGzY) - Canonical URL: https://newenglandantiaging.com/hormones/subclinical-hypothyroidism/ ## The Short Version - Subclinical hypothyroidism means TSH is above the normal range while thyroid hormone levels remain normal, and it becomes more common with age. - In the TRUST trial of 737 adults 65 and older, levothyroxine did not improve hypothyroid symptoms or tiredness after one year compared with placebo. - A 2019 BMJ guideline panel issued a strong recommendation against routine thyroid hormone treatment for most adults with subclinical hypothyroidism. - Many mildly abnormal results return to normal on repeat testing, so a single high TSH should usually be rechecked before any decision. It often starts with a routine blood panel. The thyroid-stimulating hormone, or TSH, comes back a little high, flagged in bold on the patient portal. The actual thyroid hormone, free T4, is normal. The patient has been tired lately, which is true of most adults, and a prescription for levothyroxine seems like the obvious next step. For many older adults, the evidence says it is not. ## What the numbers mean The pituitary gland releases TSH to tell the thyroid to make hormone. When the thyroid starts to lag, the pituitary pushes harder and TSH rises. In overt hypothyroidism, TSH is high and thyroid hormone is low, and treatment clearly helps. Subclinical hypothyroidism is the in-between state. TSH is above the reference range while thyroid hormone remains normal. It is common, and more common with age and in women. UK estimates [cited in The Pharmaceutical Journal](https://pharmaceutical-journal.com/article/feature/its-a-murky-business-the-row-over-levothyroxine-use-in-subclinical-disease) range from 4 to 20 percent of adults depending on the population. Part of the reason it shows up so often in older people is that TSH tends to drift upward naturally with age. A value that would be mildly high at 35 may be unremarkable at 80. ## The TRUST trial The largest test of treatment in older adults was TRUST, a European trial [published in the New England Journal of Medicine](https://doi.org/10.1056/NEJMoa1603825) in 2017. Researchers enrolled 737 adults 65 and older whose TSH stayed between 4.60 and 19.99 on repeat testing, with normal thyroid hormone levels. Their average age was about 74. Half received levothyroxine, adjusted to bring TSH into range, and half received a placebo. The medication did what it was supposed to do on paper. After a year, average TSH fell to 3.63 in the levothyroxine group compared with 5.48 in the placebo group. People did not feel any different. There was no difference between the groups in hypothyroid symptom scores or tiredness scores at one year, and no benefit on secondary measures including quality of life, grip strength, cognition and blood pressure. The investigators concluded that levothyroxine provided no apparent benefit for older people with this condition. A later analysis looked specifically at participants with the most symptoms at the start, on the theory that they might be the ones who would respond. They did not benefit either. ## Many results correct themselves One detail from the trial's recruitment deserves more attention. According to the [project's final report](https://cordis.europa.eu/project/id/278148/reporting), of the 2,647 older adults screened because of an elevated TSH, 1,645, or 62 percent, had normal TSH by the time they were retested. That was the main reason people were excluded. TSH can rise temporarily with illness, recovery from illness, certain medications and normal day-to-day variation. A single mildly high result is a reason to recheck in a few months, not a diagnosis. ## The guideline that followed In 2019 an international panel organized by [The BMJ](https://doi.org/10.1136/bmj.l2006), including patients, clinicians and methodologists, reviewed the trial evidence and issued a strong recommendation against thyroid hormones for most adults with subclinical hypothyroidism. The panel found no clinically relevant benefit for quality of life, fatigue, mood or weight and noted the burden of daily medication and lifelong monitoring. It recommended watching whether thyroid function progresses or resolves instead. The recommendation was not universally welcomed. The Society for Endocrinology and the British Thyroid Association argued it was too strong and worried that some patients whose disease progresses could be dismissed rather than monitored. That concern is a fair reminder that the alternative to a pill is follow-up, not neglect. ## When treatment still makes sense The evidence against routine treatment applies mainly to mild elevations in older adults. Different considerations apply when TSH is 10 or higher, when thyroid hormone is actually low, when someone is pregnant or trying to conceive, or when antibodies suggest an autoimmune thyroid condition likely to progress. Those decisions belong with a clinician who knows the full picture. ## If your TSH comes back high Ask whether the test should be repeated before any treatment. Ask what your free T4 was, since that number separates subclinical from overt disease. If fatigue is the main complaint, it is worth looking at other common causes, including [sleep](/mind-sleep/the-seven-hour-floor/), anemia, depression and medication side effects. And if you are already taking levothyroxine for a mildly high TSH, do not stop on your own. Talk with your prescriber about whether a supervised trial off the medication makes sense. ## What the Evidence Doesn't Settle TRUST enrolled mostly people with TSH in the mildly elevated range and few with levels near 10 or higher. The evidence is weaker for adults under 65, for people with very high symptom burden, and for those trying to become pregnant, where guidance differs. Endocrinology societies have objected that the BMJ recommendation is too sweeping. ## Notes and Sources 1. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism (TRUST). New England Journal of Medicine, 2017. https://doi.org/10.1056/NEJMoa1603825 2. Thyroid hormones treatment for subclinical hypothyroidism, a clinical practice guideline. The BMJ, 2019. https://doi.org/10.1136/bmj.l2006 3. TRUST Final Report Summary. European Commission CORDIS. https://cordis.europa.eu/project/id/278148/reporting 4. It's a murky business, the row over levothyroxine use in subclinical disease. The Pharmaceutical Journal. https://pharmaceutical-journal.com/article/feature/its-a-murky-business-the-row-over-levothyroxine-use-in-subclinical-disease --- Published by New England Anti-Aging, the health and longevity magazine of Align Wellness, 250 Centerville Rd, Building E, Warwick, RI 02886. General information only, not medical advice.